# Phalanx Biotech Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phalanx-biotech-group

- Industry: Biotechnology
- Headquarters: Hsinchu, Taiwan - China
- Website: www.phalanx.com.tw
- Total disclosed funding: $12M
- Latest round: Series B (Mar 1, 2004)
- Investors on record: 1

## About

Phalanx Biotech Group specializes in advanced genetic testing technologies, particularly high-density gene microarray chips and next-generation sequencing for healthcare applications.Phalanx Biotech Group, founded in 2002 in Hsinchu, Taiwan, focuses on genetic testing solutions. The company has raised a total of USD 11.8 mn, with its most recent funding round being Series B in March 2004, led by Industrial Technology Investment Corporation. Phalanx has completed two deals to date.Phalanx Biotech Group specializes in advanced genetic testing technologies, focusing on high-density gene microarray chips and next-generation sequencing. Their key offerings include non-invasive prenatal testing (NIPT) for fetal chromosomal abnormalities, genetic disease carrier screening, and newborn screening for conditions such as spinal muscular atrophy and congenital cytomegalovirus. They serve healthcare providers, hospitals, and clinics, with a strong presence in Taiwan and expanding influence in other Asian markets. Through their OneArray® brand, Phalanx aims to enhance prenatal care and disease prevention with its genetic insights.Phalanx Biotech Group generates revenue through direct-to-consumer and B2B transactions, primarily with healthcare institutions and clinics that utilize their genetic testing services. They provide specific tests, including prenatal genetic screening and cancer risk assessments, under contracts based on volume and service offerings. Their flagship services, such as NIPT and high-density genetic analysis, follow a structured pricing plan, enabling ongoing collaborations with medical professionals who depend on their expertise in genetic diagnostics.Phalanx Biotech Group plans to expand its product line and market reach, with new products in development aimed at enhancing genetic testing capabilities. Specific markets targeted for expansion include Southeast Asia, anticipated to commence by 2025. The recent funding of USD 11.8 mn will support these initiatives, particularly in scaling operations and enhancing R&D for new product launches.

## Funding rounds

- Series B, Mar 1, 2004, $12M — Industrial Technology Investment Corporation

## Investors

- Industrial Technology Investment Corporation (https://capitalatlas.ai/funds/industrial-technology-investment-corporation) — Series B